
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc. has demonstrated a consistent trend of positive data from clinical studies, particularly highlighting its flagship product, Ampligen, in various therapeutic applications. Notably, the successful results from a Phase 2a study assessing Ampligen for colorectal cancer and a Phase 2 study for post-COVID conditions bolster the company's position in the immuno-pharma sector. These encouraging outcomes not only validate the efficacy of Ampligen but also have the potential to serve as significant catalysts for future stock performance.
Bears say
AIM ImmunoTech Inc. reported a net loss of $2.8 million, equating to an earnings per share (EPS) of $(3.68), which fell short of estimates of $(8.00). The company faces several risks that jeopardize its financial outlook, including balance sheet and liquidity challenges, the potential failure of key product candidates to demonstrate safety and efficacy in clinical trials, and hurdles in gaining regulatory approvals. Additionally, the ability to commercialize its products effectively, secure suitable reimbursement, and navigate competitive and macroeconomic landscapes further compounds the negative outlook for the stock.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares